B7-2/GM-CSF cancer gene therapy - Radient/Jaiva/NuVax

Drug Profile

B7-2/GM-CSF cancer gene therapy - Radient/Jaiva/NuVax

Alternative Names: CIT; Combination Immunogene Therapy

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Radient Pharmaceuticals Corporation
  • Class Cancer vaccines; Cytokine genes; Gene therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in Canada (Parenteral, Injection)
  • 07 Dec 2010 Radient Pharmaceuticals forms new subsidiary NuVax Therapeutics, which will further develop this programme
  • 07 Apr 2010 Combination Immunogene Therapy is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top